UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.06 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 73,888 shares of the company's stock after purchasing an additional 10,427 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.15% of Mirum Pharmaceuticals worth $3,055,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in MIRM. Janus Henderson Group PLC lifted its holdings in Mirum Pharmaceuticals by 2.3% during the fourth quarter. Janus Henderson Group PLC now owns 4,581,642 shares of the company's stock worth $189,481,000 after acquiring an additional 101,358 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Mirum Pharmaceuticals by 10.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company's stock worth $58,831,000 after acquiring an additional 138,623 shares in the last quarter. Geode Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock worth $39,016,000 after acquiring an additional 7,147 shares in the last quarter. Clearbridge Investments LLC increased its position in Mirum Pharmaceuticals by 2.0% during the fourth quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock worth $37,518,000 after buying an additional 18,217 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its position in Mirum Pharmaceuticals by 5.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 782,354 shares of the company's stock worth $32,350,000 after buying an additional 40,986 shares during the last quarter.

Insider Activity

In related news, SVP Jolanda Howe sold 57,606 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the transaction, the senior vice president now directly owns 4,841 shares of the company's stock, valued at approximately $214,698.35. This trade represents a 92.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Peetz sold 27,279 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the transaction, the chief executive officer now directly owns 138,641 shares of the company's stock, valued at $6,129,318.61. The trade was a 16.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,764 shares of company stock valued at $4,109,161. Insiders own 22.87% of the company's stock.

Analysts Set New Price Targets

MIRM has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $73.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. JMP Securities increased their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research note on Friday, May 9th. Finally, Raymond James restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $60.73.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $44.65 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.21 billion, a P/E ratio of -22.10 and a beta of 0.95. The company's 50 day moving average price is $42.57 and its two-hundred day moving average price is $44.71. Mirum Pharmaceuticals, Inc. has a 52 week low of $24.07 and a 52 week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same period in the previous year, the business earned ($0.54) EPS. The business's revenue for the quarter was up 61.2% on a year-over-year basis. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.